Comet Therapeutics
Comet Therapeutics is a Cambridge, MA-based biotech founded in 2018 that develops therapies for orphan neurological disorders. The company raised $28.5 million in a 2019 Series 2 led by Canaan Partners and Sofinnova Partners, and its operating domain is currently listed for sale.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Comet Therapeutics does
Comet Therapeutics is a Cambridge, Massachusetts-based biotechnology company founded in 2018 that develops therapies intended to treat orphan neurological disorders. The company operated as a small, privately held, for-profit entity with 1-10 employees, and is led by CEO and President David de Graaf, founder and CTO Enej Kuscer, Chief Scientific Officer Arthur Taveres, and independent Chairman Peter Van Vlasselaer.
The company raised a single disclosed financing round: a $28.5 million Series 2 on June 19, 2019, co-led by Canaan Partners and Sofinnova Partners with participation from Mission BioCapital and Inkef. No follow-on financings, partnerships, in-licensing deals, or pipeline disclosures are documented in the available data, and no products, indications, modality (small molecule, biologic, gene therapy, etc.), or clinical-stage assets are described.
Material operational signals point to dormancy or wind-down: the company's website domain (comettherapeutics.com) is listed for sale on HugeDomains at $4,295, with no substantive company content at that address. No revenue, customers, commercial partnerships, regulatory filings, or current headcount detail is available. As a result, the verifiable footprint is limited to its 2019 capital event and founding leadership, and any investment-grade assessment should treat the entity as effectively inactive absent new primary disclosures.
Comet Therapeutics firmographics
Firmographics- Name
- Comet Therapeutics
- Website
- https://comettherapeutics.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 1–10 employees
- Short description
- Comet Therapeutics is a Cambridge, MA-based biotech founded in 2018 that develops therapies for orphan neurological disorders. The company raised $28.5 million in a 2019 Series 2 led by Canaan Partners and Sofinnova Partners, and its operating domain is currently listed for sale.
- Ownership category
- akta.pro rank
Comet Therapeutics industry classification
Industry- Product category
- Neurological Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Comet Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Comet Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Comet Therapeutics product offering
Product offeringCore offering
Comet Therapeutics is a biotechnology company developing therapies intended to treat orphan neurological disorders. The company focuses on drug discovery and development for rare diseases of the central nervous system, targeting conditions with limited existing treatment options.
Product overview
The source data is from a domain for sale listing page at HugeDomains.com for the domain name CometTherapeutics.com. This is not an active company website but rather a domain broker page indicating that the comettherapeutics.com domain is available for purchase at $4,295 (or $178.96/month for 24 months). No actual company information, products, or services for Comet Therapeutics were found in the available source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Orphan neurological disorder therapies
Companies that use Comet Therapeutics
Customer profileIdeal customer profiles1 record
Comet Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Comet Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
Comet Therapeutics competitors and assessment
Company assessmentDirect peers
- Passage Bio: Genetic medicines company focused on rare monogenic CNS disorders. Comparable therapeutic area (rare neuro) and platform-stage development profile.
- IntraBio: Late-stage rare disease biotech with neurological indications including Niemann-Pick disease type C. Comparable in orphan neuro focus and small-cap development model.
- Minoryx Therapeutics: Clinical-stage biotech developing therapies for rare neurological disorders, most notably X-linked adrenoleukodystrophy. Directly comparable to Comet in therapeutic area (orphan neuro) and stage profile.
Broad incumbents
- BridgeBio Pharma: Diversified rare-disease biotech with CNS programs in its portfolio. Comparable orphan-disease strategic orientation but operates as a multi-asset, publicly-listed holding company.
- BioMarin Pharmaceutical: Established rare-disease leader with marketed neurological assets (e.g., enzyme replacement for CLN2). Comparable in orphan neuro positioning but at full commercial scale.
- Ultragenyx Pharmaceutical: Commercial-stage rare-disease company with multiple neurological programs including for rare metabolic and CNS disorders. Comparable orphan-drug strategy and Cambridge-area presence.
- Denali Therapeutics: Larger biotech developing therapeutics for neurodegenerative and rare neurological diseases. Comparable in CNS/rare neuro focus but operates at meaningfully greater scale and breadth.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Comet Therapeutics social profiles
Digital presenceComet Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Comet Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Comet Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Comet Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Comet Therapeutics
What does Comet Therapeutics do?
Comet Therapeutics is a biotechnology company developing therapies intended to treat orphan neurological disorders. The company focuses on drug discovery and development for rare diseases of the central nervous system, targeting conditions with limited existing treatment options.
When was Comet Therapeutics founded?
Comet Therapeutics was founded in 2018. It employs 1 to 10 people.
Where is Comet Therapeutics based?
Comet Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Comet Therapeutics's main competitors?
Direct peers on record are Passage Bio, IntraBio and Minoryx Therapeutics. Broad incumbents are BridgeBio Pharma, BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Denali Therapeutics.
Does Comet Therapeutics have an API?
No public API is recorded for Comet Therapeutics.
What industry is Comet Therapeutics in?
Comet Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.